Updated 12:17 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 58,232.43 -0.96%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $58,232 −0.96% VIX 35.89 +26.20% latest tape · as of 12:17 UTC
The Screen · Healthcare · Biotechnology

Ardelyx, Inc. logoArdelyx, Inc.

ARDX · Nasdaq · USD · Market cap $865M · 489 employees

Ardelyx, Inc.

FAIL · Does not pass the screen
2.99 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price2.99 USD at the 20 Nov 2026 close
  • Fair value4.55. Our model only; the analyst targets sit too far from the price to cross-check it.
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 16.94)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $4.16 to $6.24, base estimate $4.55 (screen dated 2026-11-20).

Current read
Distribution ?
Undervalued · screened 2026-11-20
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 16.94, read 2026-11-18
  • Ethical does not pass the values gate
Price2.99 USD
Fair value4.55Our model only; the analyst targets sit too far from the price to cross-check it.
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-10Read Distribution2.93+2.0% to today Markdown gives way to Distribution after a 16% slide in 7 weeks
2026-09-24Read Markdown3.50-14.6% to today ✓Distribution gives way to Markdown after a 12% slide in 5 weeks
2026-08-21Read Distribution3.97-24.7% to today ✓Accumulation gives way to Distribution after a 30% slide in 7 weeks
2026-07-02Read Accumulation5.69-47.5% to today First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Ardelyx, Inc. holds its Distribution at $2.99. Consolidating, no directional conviction, held for 6 days.

As held on the ledger · 2026-11-20
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 6 days
Price at the screen$2.99
ValuationN/A trailing · 13.89 forward price to earnings
Values screenFAIL · score 70.0
Beta0.73
The Workings

Five Screens: ARDX's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 41.46% Below 33% Fail
Interest-bearing cash 39.21% Below 33% Fail
Receivables 27.88% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Ardelyx,'s business is in a permissible area, but its interest-bearing debt is about 41% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when ARDX's ethical verdict changes

Today ARDX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our model only; the analyst targets sit too far from the price to cross-check it.

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 34% discount to our $4.55 fair value, 23.80% revenue growth.

Method.

4.16Conservative4.55Base case6.24Growth case 2.99Price

USD, 2026-11-20 screen. A 34.3% under base.

The Street's Range
8.00Street low 13.50Street average 18.00Street high 2.99Price

Street: 10 covering, consensus Strong Buy. Average target +352%.

Chart
The Business, in Plain Words

Gut Drug Maker Grows Fast But Stays Unprofitable

Picture a patient with stubborn IBS finally getting relief from a new pill. Ardelyx has built real revenue momentum at 28 percent growth, a forward multiple of just 10 times and an ethical screen that clears. The share price sits well below the analyst median target, yet the business still posts a 14 percent negative profit margin and negative 39 percent return on equity.

That combination keeps the opportunity rating at none. A low multiple on peak sales can look attractive until the next clinical or reimbursement setback arrives, and the unknown moat offers little protection if bigger players move in. The numbers show a company that has not yet proved it can convert growth into consistent cash.

Risk therefore sits in the execution gap between current losses and future profits. Currency or regulatory shocks in overseas markets would add further pressure. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E13.9xcheap for a company growing this fast
EPS, trailing-0.23
EPS, forward0.25
Revenue growth+23.8%strong top-line growth
Profit margin-12.4%currently unprofitable
Return on equity-38.6%not currently earning a positive return on equity
FCF yield2.08%
Debt to equity1.90a meaningful debt load worth watching
Current ratio3.34comfortably covers its short-term bills
Beta0.73steadier than the market
Short interest, float0.09%
52-week range3.73 - 8.40
Market cap$865M
Employees489

ARDX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Distribution $3.12 +1.0% Entry 22
2026-11-17 Distribution $3.09 +5.5% Entry 21
2026-11-10 Distribution · changed $2.93 -3.3% Entry 20

The framework has shifted from markdown to distribution since the last review.

2026-11-03 Markdown $3.03 +0.0% Entry 19
2026-11-02 Markdown $3.03 +0.0% Entry 18
2026-11-01 Markdown $3.03 -2.3% Entry 17
2026-10-31 Markdown $3.10 +0.0% Entry 16
2026-10-30 Markdown $3.10 +0.0% Entry 15
2026-10-29 Markdown $3.10 -5.2% Entry 14
2026-10-28 Markdown $3.27 +0.0% Entry 13

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Related Securities · Others in ARDX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $6.61 -14.3% · $857 -14.3%
2 months $6.18 -8.3% · $917 -8.3%
3 months $5.66 +0.1% · $1,001 +0.1%
6 months $5.90 -4.0% · $960 -4.0%
1 year $3.74 +51.5% · $1,515 +51.5%
2 years $6.46 -12.3% · $877 -12.3%
3 years $3.98 +42.3% · $1,423 +42.3%
5 years $7.38 -23.2% · $768 -23.2%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ARDX does next, these words stay.

Ardelyx, Inc. · ARDX · Distribution · $2.99
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.